Education
About Us
Working with TipRanks
Follow Us
Ipsen (GB:0MH6)
LSE:0MH6
0MH6 Stock Chart & Stats
€160.20
€1.07(0.92%)
At close: 4:00 PM EST
€160.20
€1.07(0.92%)
Day’s Range― - ―
52-Week Range€88.05 - €165.10
Previous CloseN/A
Volume2.29K
Average Volume (3M)63.40K
Market Cap
€13.66B
Enterprise Value€13.18B
Total Cash (Recent Filing)€1.53B
Total Debt (Recent Filing)€1.05B
Price to Earnings (P/E)30.8
Beta0.90
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.02
Shares Outstanding83,814,530
10 Day Avg. Volume42,069
30 Day Avg. Volume63,401
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€141.33Price Target Upside-11.78% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)11.93
Revenue Forecast (FY)€4.06B
Bulls Say, Bears Say
Bulls Say
Specialty Biopharma PortfolioIpsen's targeted specialty portfolio (oncology, neurology, rare diseases) and established brands such as Somatuline and Dysport create durable therapeutic demand, higher barriers to generic competition and steady commercial channels, supporting repeatable revenue and strategic R&D focus.
Consistent Revenue Growth And Solid MarginsMulti-year top-line growth combined with healthy 2025 profitability (net margin ~12%, EBITDA margin ~30%) indicates underlying business strength, enabling investment in R&D and commercialization while supporting resilience through industry cycles and sustaining operational cash generation.
Conservative Capital StructureA low debt-to-equity ratio and growing equity base provide financial flexibility for long-term investment, M&A or R&D spending, reducing solvency risk and supporting credit strength relative to peers, which is beneficial for sustaining strategic initiatives over months to years.
Bears Say
Margin Compression Since 2021–2023Meaningful decline in net margins versus prior years implies rising costs or adverse product mix, which reduces the firm's ability to convert revenue into sustainable profits. If structural, this pressures free cash flow, limits reinvestment capacity and can weaken long-term return on capital.
Sharp Increase In Total Debt In 2025A material step-up in debt levels shortens the runway of conservative leverage and raises interest and refinancing risk. Even from a low base, rising debt can constrain strategic flexibility, increase fixed costs and make funding future R&D or acquisitions more expensive or conditional.
Volatile Free-cash-flow ConversionInconsistent FCF generation and variability versus earnings indicate execution or working-capital volatility. This undermines predictability of funding for R&D, dividends or debt servicing and raises the risk that operational swings could force reactive financing or deferred investments.
Ipsen News
0MH6 FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest share price was €88.05 and its highest was €165.10 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €13.66B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Jul 23, 2026 which is in 145 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Feb 12, 2026. The company reported €6.02 earnings per share for the quarter, beating the consensus estimate of €5.527 by €0.493.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Overvalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €6.02 in its last earnings report, beating expectations of €5.527. Following the earnings report the stock price went up 7.349%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in GB:0MH6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
0MH6 Stock 12 Month Forecast
Average Price Target
€141.33
▼(-11.78% Downside)
Technical Analysis
Options Prices
Currently, No data available
---